Multiple courses of intralesional collagenase injections for Peyronie disease: a retrospective analysis.


Journal

The journal of sexual medicine
ISSN: 1743-6109
Titre abrégé: J Sex Med
Pays: Netherlands
ID NLM: 101230693

Informations de publication

Date de publication:
14 02 2023
Historique:
received: 21 05 2022
revised: 08 11 2022
accepted: 10 11 2022
pubmed: 11 2 2023
medline: 22 2 2023
entrez: 10 2 2023
Statut: ppublish

Résumé

In the original clinical trials evaluating intralesional collagenase Clostridium histolyticum for Peyronie disease (PD), treatment protocols were limited to 8 injections. We sought to describe our single-center experience with the use of multiple rounds (>8 injections) of intralesional collagenase in patients with PD. We conducted a retrospective analysis of all patients with PD receiving intralesional collagenase injections at our institution from October 2015 through December 2020. Some patients who completed 1 round of treatment elected to undergo additional rounds (16 or 24 injections) based on persistent curvature and presence of penile plaque. Clinical improvement was defined as a 20% reduction in penile curvature from the start of a given round of treatment to the end of that round of treatment. We measured erect penile curvature before and after each round and collected demographics, medical and surgical history, curvature outcomes, and treatment-related adverse events. The primary outcome was the reduction in penile curvature after multiple rounds of treatment with intralesional collagenase injections in patients with PD. A total of 330 patients underwent intralesional collagenase injections for PD, of whom 229 completed at least 8 injections and underwent pre- and posttreatment erect penile goniometry. An overall 42.8% (98/229), 38.6% (22/57), and 12.5% (1/8) of patients achieved clinical improvement after 1 round of therapy (8 injections), 2 rounds (16 injections), and 3 rounds (24 injections), respectively. Mean degree and mean percentage improvement of penile curvature for the start and end of each round of treatment were 8.3° and 16.4% (after 1 round), 7.2° and 16.8% (after 2 rounds), and 3.3° and 8.1% (after 3 rounds). Bruising was the most common complication, with an incidence of at least 50% in each round. Knowledge of patient responses to multiple rounds of intralesional collagenase injections may help guide physicians in management and counseling of patients regarding PD treatment options. This is the first study to evaluate multiple rounds (>8 injections) of intralesional collagenase for PD. Limitations include retrospective analysis and smaller sample size among patients undergoing 3 rounds (24 injections). For patients who did not achieve clinical improvement after 1 round of treatment, an additional round may be beneficial. However, no real improvement was observed for patients undergoing a third round.

Sections du résumé

BACKGROUND
In the original clinical trials evaluating intralesional collagenase Clostridium histolyticum for Peyronie disease (PD), treatment protocols were limited to 8 injections.
AIM
We sought to describe our single-center experience with the use of multiple rounds (>8 injections) of intralesional collagenase in patients with PD.
METHODS
We conducted a retrospective analysis of all patients with PD receiving intralesional collagenase injections at our institution from October 2015 through December 2020. Some patients who completed 1 round of treatment elected to undergo additional rounds (16 or 24 injections) based on persistent curvature and presence of penile plaque. Clinical improvement was defined as a 20% reduction in penile curvature from the start of a given round of treatment to the end of that round of treatment. We measured erect penile curvature before and after each round and collected demographics, medical and surgical history, curvature outcomes, and treatment-related adverse events.
OUTCOME
The primary outcome was the reduction in penile curvature after multiple rounds of treatment with intralesional collagenase injections in patients with PD.
RESULTS
A total of 330 patients underwent intralesional collagenase injections for PD, of whom 229 completed at least 8 injections and underwent pre- and posttreatment erect penile goniometry. An overall 42.8% (98/229), 38.6% (22/57), and 12.5% (1/8) of patients achieved clinical improvement after 1 round of therapy (8 injections), 2 rounds (16 injections), and 3 rounds (24 injections), respectively. Mean degree and mean percentage improvement of penile curvature for the start and end of each round of treatment were 8.3° and 16.4% (after 1 round), 7.2° and 16.8% (after 2 rounds), and 3.3° and 8.1% (after 3 rounds). Bruising was the most common complication, with an incidence of at least 50% in each round.
CLINICAL IMPLICATIONS
Knowledge of patient responses to multiple rounds of intralesional collagenase injections may help guide physicians in management and counseling of patients regarding PD treatment options.
STRENGTHS AND LIMITATIONS
This is the first study to evaluate multiple rounds (>8 injections) of intralesional collagenase for PD. Limitations include retrospective analysis and smaller sample size among patients undergoing 3 rounds (24 injections).
CONCLUSION
For patients who did not achieve clinical improvement after 1 round of treatment, an additional round may be beneficial. However, no real improvement was observed for patients undergoing a third round.

Identifiants

pubmed: 36763912
pii: 6986019
doi: 10.1093/jsxmed/qdac030
doi:

Substances chimiques

Collagenases EC 3.4.24.-
Microbial Collagenase EC 3.4.24.3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

200-204

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of The International Society of Sexual Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Michelle K Li (MK)

Division of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, United States.

John T Sigalos (JT)

Division of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, United States.

Dar A Yoffe (DA)

Division of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, United States.

Neilufar Modiri (N)

Division of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, United States.

Ming-Yeah Hu (MY)

Division of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, United States.

Thomas W Gaither (TW)

Division of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, United States.

Alvaro Santamaria (A)

Division of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, United States.

Dyvon T Walker (DT)

School of Medicine, University of Colorado, Aurora, CO 80045, United States.

Keith V Regets (KV)

Division of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, United States.

Jesse N Mills (JN)

Division of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, United States.

Sriram V Eleswarapu (SV)

Division of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH